VHL - Von Hippel-Lindau Syndrome research hub

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

This study is testing a new medicine called belzutifan for people with Von Hippel-Lindau (VHL) disease who have kidney cancer. It aims to see how well the medicine works and if it's safe to use. Patients will take the medicine continuously and have regular scans to check their progress.